Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release

Fangjian Guo, W Timothy Garvey, Fangjian Guo, W Timothy Garvey

Abstract

Objective: To assess the ability of medication-assisted weight loss to prevent diabetes as a function of the baseline weighted Cardiometabolic Disease Staging (CMDS) score.

Research design and methods: We pooled data from 3,040 overweight and obese participants in three randomized controlled trials-CONQUER, EQUIP, and SEQUEL-assessing efficacy and safety of phentermine/topiramate extended release (ER) for weight loss. In these double-blind phase III trials, overweight/obese adult patients were treated with a lifestyle intervention and randomly assigned to placebo versus once-daily oral phentermine/topiramate ER. The weighted CMDS score was calculated using baseline quantitative clinical data including waist circumference, blood glucose, blood pressure, and blood lipids. Incident diabetes was defined based on serial measures of fasting glucose, 2-h oral glucose tolerance test glucose, and/or HbA1c.

Results: The absolute decrease in 1-year diabetes incidence rates in subjects treated with medication versus placebo was greatest in those with high-risk CMDS scores at baseline (10.43-6.29%), intermediate in those with moderate CMDS risk (4.67-2.37%), and small in the low-risk category (1.51-0.67%). The number of participants needed to treat to prevent one new case of diabetes over a 56-week period was 24, 43, and 120 in those with baseline CMDS scores of ≥60, 30-59, and 0-29, respectively.

Conclusions: Numbers needed to treat to prevent one case of type 2 diabetes are markedly lower in patients with high-risk scores. CMDS can be used to quantify risk of diabetes in overweight/obese individuals and predict the effectiveness of weight-loss therapy to prevent diabetes.

Trial registration: ClinicalTrials.gov NCT00553787 NCT00554216 NCT00796367.

© 2017 by the American Diabetes Association.

Figures

Figure 1
Figure 1
Risk for incident diabetes by CMDS score group and treatment arm.
Figure 2
Figure 2
Number needed to treat to prevent one case of diabetes over 56 weeks.

References

    1. Power C, Pinto Pereira SM, Law C, Ki M. Obesity and risk factors for cardiovascular disease and type 2 diabetes: investigating the role of physical activity and sedentary behaviour in mid-life in the 1958 British cohort. Atherosclerosis 2014;233:363–369
    1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014;311:806–814
    1. Smith SR, Weissman NJ, Anderson CM, et al. .; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group . Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245–256
    1. Allison DB, Gadde KM, Garvey WT, et al. . Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330–342
    1. Arena Pharmaceuticals and Eisai Announce FDA Approval of BELVIQ (lorcaserin HCl) for Chronic Weight Management in Adults who are Overweight with a Comorbidity or Obese [article online], 2012. Available from . Accessed on 1 February 2012.
    1. Prescribing information for QSYMIA [Internet], 2012. Available from . Accessed on 1 February 2012.
    1. Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American Association of Clinical Endocrinologists’ position statement on obesity and obesity medicine. Endocr Pract 2012;18:642–648
    1. National Institutes of Health Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. Obes Res 1998;6(Suppl. 2):51S–209S
    1. Klein S, Burke LE, Bray GA, et al. .; American Heart Association Council on Nutrition, Physical Activity, and Metabolism . Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952–2967
    1. American Diabetes Association Standards of medical care in diabetes--2012. Diabetes Care 2012;35(Suppl. 1):S11–S63
    1. Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring) 2014;22:110–118
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421
    1. Cleeman JI, Grundy SM, Becker D, et al. .; Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497
    1. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066–3072
    1. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007;167:1068–1074
    1. Schmidt MI, Duncan BB, Bang H, et al. .; Atherosclerosis Risk in Communities Investigators . Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 2005;28:2013–2018
    1. Guo F, Garvey WT. Development of a weighted Cardiometabolic Disease Staging (CMDS) system for the prediction of future diabetes. J Clin Endocrinol Metab 2015;100:3871–3877
    1. Friedman GD, Cutter GR, Donahue RP, et al. . CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988;41:1105–1116
    1. The ARIC investigators The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989;129:687–702
    1. Gadde KM, Allison DB, Ryan DH, et al. . Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341–1352
    1. Garvey WT, Ryan DH, Look M, et al. . Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297–308
    1. Garvey WT, Ryan DH, Henry R, et al. . Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care 2014;37:912–921
    1. Hamman RF, Wing RR, Edelstein SL, et al. . Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006;29:2102–2107
    1. Carlsson LM, Peltonen M, Ahlin S, et al. . Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012;367:695–704
    1. Booth H, Khan O, Prevost T, et al. . Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. Lancet Diabetes Endocrinol 2014;2:963–968
    1. Guo F, Garvey WT. Trends in cardiovascular health metrics in obese adults: National Health and Nutrition Examination Survey (NHANES), 1988-2014. J Am Heart Assoc 2016;5:e003619.
    1. Centers for Disease Control and Prevention (CDC) Trends in intake of energy and macronutrients--United States, 1971-2000. MMWR Morb Mortal Wkly Rep 2004;53:80–82
    1. Sijtsma FP, Meyer KA, Steffen LM, et al. . Longitudinal trends in diet and effects of sex, race, and education on dietary quality score change: the Coronary Artery Risk Development in Young Adults study. Am J Clin Nutr 2012;95:580–586
    1. Li R, Serdula M, Bland S, Mokdad A, Bowman B, Nelson D. Trends in fruit and vegetable consumption among adults in 16 US states: Behavioral Risk Factor Surveillance System, 1990-1996. Am J Public Health 2000;90:777–781
    1. Bazzano AT, Zeldin AS, Diab IR, Garro NM, Allevato NA, Lehrer D; WRC Project Oversight Team . The Healthy Lifestyle Change Program: a pilot of a community-based health promotion intervention for adults with developmental disabilities. Am J Prev Med 2009;37(Suppl. 1):S201–S208
    1. Jackson L. Translating the Diabetes Prevention Program into practice: a review of community interventions. Diabetes Educ 2009;35:309–320
    1. Guo F, He D, Zhang W, Walton RG. Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010. J Am Coll Cardiol 2012;60:599–606
    1. Egan BM, Li J, Hutchison FN, Ferdinand KC. Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation 2014;130:1692–1699
    1. Knowler WC, Fowler SE, Hamman RF, et al. .; Diabetes Prevention Program Research Group . 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677–1686
    1. Garvey WT, Mechanick JI, Brett EM, et al. .; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines . American Association of Clinical Andocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity executive summary. Endocr Pract 2016;22:842–884
    1. Garvey WT. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. Endocr Pract 2013;19:864–874
    1. Garvey WT, Garber AJ, Mechanick JI, et al. .; The Aace Obesity Scientific Committee . American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract 2014;20:977–989
    1. D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–753
    1. Shafizadeh TB, Moler EJ, Kolberg JA, et al. . Comparison of accuracy of diabetes risk score and components of the metabolic syndrome in assessing risk of incident type 2 diabetes in Inter99 cohort. PLoS One 2011;6:e22863.
    1. Padwal RS, Pajewski NM, Allison DB, Sharma AM. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ 2011;183:E1059–E1066

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner